AC Immune Reports Results of ACI-24.060 in P-Ib/II Trial for the Treatment of Alzheimer’s Disease and Down Syndrome
Shots:
- The P-Ib/II clinical trial (ABATE) evaluates the safety, tolerability, immunogenicity & PD effects of ACI-24.060 in patients with Alzheimer’s disease & Down syndrome whose brain Abeta pathology was confirmed through PET scan
- The results depicted that a low dose of ACI-24.060 generated an anti-Abeta Ab at 6wks. along with a safe & tolerable response. The evaluation of higher doses of ACI-24.060 & the screening of DS patients for the 2nd portion of the study has initiated
- ACI-24.060 was developed using AC Immune’s SupraAntigen platform to enhance the formation of broad-spectrum protective antibodies & can potentially inhibit plaque formation & increase plaque clearance which reduces/prevents disease progression
Ref: GlobeNewswire | Image: AC Immune
Related News:- AC Immune Report Results of Semorinemab in P-II Lauriet Study for the Treatment of Alzheimer's Disease
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
![Life Molecular Imaging’s [18F] PI-2620 Gains the US FDA’s Fast Track Designation for PET Imaging in Various Neurodegenerative Disorders](https://pharmashots.com/public/images/20240829173251_original_43.webp)
